Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

NHS Digital Health Check begins trial to ease pressure on services

The digital service could prevent around 1,600 heart attacks and strokes per year

Infographic: Therapy Watch Hyperlipidaemia

Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study.

Inizio

Article: The rise of the healthcare influencer

In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space.

Inizio

- PMLiVE

EMA’s emergency task force backs bivalent COVID-19 vaccines for primary vaccination

National authorities may decide to use the vaccines in their primary vaccination campaigns

- PMLiVE

Gilead announces positive new data for Trodelvy in metastatic breast cancer

The treatment demonstrated consistent efficacy across Trop-2 expression levels

- PMLiVE

Pfizer and Clear Creek Bio partner on COVID-19 antiviral research programme

The companies will identify a papain-like protease candidate to progress into the clinic

- PMLiVE

Lilly shares positive Verzenio data as adjuvant early breast cancer therapy

Results were shared in The Lancet Oncology and at the San Antonio Breast Cancer Symposium

- PMLiVE

ORIGINS cements its specialist position with a truly patient focused offering

Origins are the patient focused specialists that create and deliver strategy, insights, experience data and solutions across the product lifecycle

Origins – The Patient Focused Specialists

- PMLiVE

Pfizer/BioNTech submit FDA application for BA.4/BA.5 COVID-19 vaccine in children under five

The vaccine is already authorised as a booster for ages five years and older in the US and EU

- PMLiVE

Antibiotics may be given to UK schools affected by strep A

Latest UKHSA data shows scarlet fever cases continue to be higher than usual for this time of year

- PMLiVE

LEO Pharma’s delgocitinib cream shows promise in phase 3 chronic hand eczema study

There are no topical treatments specifically developed and approved for moderate-to-severe CHE

- PMLiVE

Valneva’s chikungunya vaccine candidate shows promise in antibody persistence trial

The trial results demonstrated a 99% seroresponse rate 12 months after a single-dose vaccination

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links